XL413 e F Treatment with Abiraterone significantly inhibited

Treatment with Abiraterone significantly inhibited CRPC progression in the robustly growing subset

A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics

or 7 mg/kg i

InChi: InChI=1S/C22H17N3O6/c1-2-21(26)23-13-17(11-15-3-7-19(8-4-15)24(28)29)22(27)18(14-23)12-16-5-9-20(10-6-16)25(30)31/h2-12H

Salifazide

XL413 e F Treatment with Abiraterone significantly inhibitedBMS 863233, also known as XL 413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS 863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7 overexpressing tumor cells. CDC7, a serine threonine kinase